Francesca Cottini

2.0k total citations
59 papers, 1.1k citations indexed

About

Francesca Cottini is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Francesca Cottini has authored 59 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 32 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Francesca Cottini's work include Multiple Myeloma Research and Treatments (42 papers), Protein Degradation and Inhibitors (15 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Francesca Cottini is often cited by papers focused on Multiple Myeloma Research and Treatments (42 papers), Protein Degradation and Inhibitors (15 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Francesca Cottini collaborates with scholars based in United States, Italy and Japan. Francesca Cottini's co-authors include Teru Hideshima, Kenneth C. Anderson, Paul G. Richardson, Rikio Suzuki, Jana Jakubı́ková, Hiroto Ohguchi, Nikhil C. Munshi, Güllü Görgün, Naoya Mimura and Yu‐Tzu Tai and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Francesca Cottini

51 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesca Cottini United States 15 616 321 283 181 174 59 1.1k
Sonja Mandl–Weber Germany 16 511 0.8× 241 0.8× 225 0.8× 153 0.8× 117 0.7× 26 921
Yi L. Hwa United States 22 922 1.5× 612 1.9× 426 1.5× 87 0.5× 190 1.1× 64 1.4k
Andrija Bogdanović Serbia 17 294 0.5× 466 1.5× 141 0.5× 130 0.7× 279 1.6× 96 894
Sujun Gao China 18 357 0.6× 427 1.3× 217 0.8× 198 1.1× 283 1.6× 96 1.0k
William Tse United States 17 419 0.7× 397 1.2× 159 0.6× 54 0.3× 170 1.0× 50 905
Jie Ding China 16 604 1.0× 115 0.4× 205 0.7× 79 0.4× 60 0.3× 57 1.2k
Rajendra Ramsamooj United States 14 256 0.4× 99 0.3× 231 0.8× 133 0.7× 70 0.4× 32 938
Ann Janssens Belgium 20 332 0.5× 421 1.3× 322 1.1× 579 3.2× 603 3.5× 100 1.5k
Greg Ball United States 13 235 0.4× 413 1.3× 112 0.4× 68 0.4× 306 1.8× 34 861
Kumar Vivek United States 11 416 0.7× 199 0.6× 145 0.5× 79 0.4× 95 0.5× 20 1.0k

Countries citing papers authored by Francesca Cottini

Since Specialization
Citations

This map shows the geographic impact of Francesca Cottini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Cottini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Cottini more than expected).

Fields of papers citing papers by Francesca Cottini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Cottini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Cottini. The network helps show where Francesca Cottini may publish in the future.

Co-authorship network of co-authors of Francesca Cottini

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Cottini. A scholar is included among the top collaborators of Francesca Cottini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Cottini. Francesca Cottini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boghdadly, Zeinab El, Nidhi Sharma, Naresh Bumma, et al.. (2025). Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab. PubMed. 2(3). 100097–100097. 1 indexed citations
2.
Mansour, Anthony G., Qiuhong Zhao, Francesca Cottini, et al.. (2024). Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. SHILAP Revista de lepidopterología. 5(4). 407–419.
3.
Chen, Pei, Naresh Bumma, Abdullah Khan, et al.. (2024). Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact. Blood. 144(Supplement 1). 4717–4717. 1 indexed citations
4.
Broughton, Megan, Nidhi Sharma, Abdullah Khan, et al.. (2024). Evaluation of Characteristics and Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia Treated with Modern Therapies. Blood. 144(Supplement 1). 6980–6980.
5.
Benson, Don, et al.. (2024). CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma. Leukemia. 38(8). 1777–1786. 4 indexed citations
6.
Sharma, Nidhi, Qiuhong Zhao, Francesca Cottini, et al.. (2023). Survival outcomes following autologous stem cell transplant with melphalan 140mg/m 2 versus 200mg/m 2 preparative regimens in patients with multiple myeloma. Leukemia & lymphoma. 64(7). 1315–1321.
7.
Longo, Larissa V. G., et al.. (2023). TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma. Haematologica. 109(2). 578–590. 6 indexed citations
8.
Miller, Cecelia, et al.. (2023). Transformed Plasmablastic Lymphoma Presenting With Marked Lymphocytosis and Spontaneous Tumor Lysis Syndrome. Journal of Hematology. 12(1). 49–58. 1 indexed citations
9.
10.
Zhao, Qiuhong, Nidhi Sharma, Naresh Bumma, et al.. (2023). Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma. Frontiers in Oncology. 13. 1216461–1216461. 1 indexed citations
11.
Khan, Abdullah, Muhammad Salman Faisal, Qiuhong Zhao, et al.. (2022). Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience. Clinical Lymphoma Myeloma & Leukemia. 23(3). e182–e189. 3 indexed citations
12.
Malek, Ehsan, Sajjeev Jagannathan, Nikhil Vad, et al.. (2016). Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia. 31(3). 645–653. 48 indexed citations
13.
Cottini, Francesca, Teru Hideshima, Rikio Suzuki, et al.. (2015). Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discovery. 5(9). 972–987. 87 indexed citations
14.
Suzuki, Rikio, Shohei Kikuchi, Takeshi Harada, et al.. (2015). Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS ONE. 10(12). e0143847–e0143847. 19 indexed citations
15.
Hideshima, Teru, Francesca Cottini, Hiroto Ohguchi, et al.. (2015). Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer Journal. 5(5). e312–e312. 53 indexed citations
16.
Cirstea, Diana, Loredana Santo, Teru Hideshima, et al.. (2014). Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics. 13(11). 2489–2500. 24 indexed citations
17.
Mimura, Naoya, Teru Hideshima, Toshiyasu Shimomura, et al.. (2014). Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. Cancer Research. 74(16). 4458–4469. 66 indexed citations
18.
Cirstea, Diana, Teru Hideshima, Loredana Santo, et al.. (2013). Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 27(12). 2366–2375. 47 indexed citations
19.
Suzuki, Rikio, Ralph Mazitschek, Güllü Görgün, et al.. (2013). Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 28(3). 680–689. 131 indexed citations
20.
Fazi, Claudia, Antonis Dagklis, Francesca Cottini, et al.. (2010). Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. Cytometry Part B Clinical Cytometry. 78B(S1). S61–8. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sonja Mandl–Weber Breakdown of academic impact, for papers by Yi L. Hwa Breakdown of academic impact, for papers by Andrija Bogdanović Breakdown of academic impact, for papers by Sujun Gao Breakdown of academic impact, for papers by William Tse Breakdown of academic impact, for papers by Jie Ding Breakdown of academic impact, for papers by Rajendra Ramsamooj Breakdown of academic impact, for papers by Ann Janssens Breakdown of academic impact, for papers by Greg Ball Breakdown of academic impact, for papers by Kumar Vivek
Rankless by CCL
2026